Related Experiment Video
Updated: Sep 8, 2025
Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System
Published on: October 5, 2015
Lessons from Acquired Natural Immunity and Clinical Trials to Inform Next-Generation Human Cytomegalovirus Vaccine
Xintao Hu1, Hsuan-Yuan Wang1,2, Claire E Otero1,2
1Department of Pediatrics, Weill Cornell Medicine, New York, New York, USA;
Insights
An effective human cytomegalovirus (HCMV) vaccine is crucial for preventing congenital disease and immunocompromised patient illness. This review analyzes immunity, past trials, and animal models to propose novel strategies for next-generation HCMV vaccines.
Area of Science:
- Virology
- Immunology
- Vaccinology
Background:
- Human cytomegalovirus (HCMV) is a leading cause of congenital defects and a significant threat to immunocompromised individuals.
- Despite extensive research for over 50 years, an effective HCMV vaccine remains unavailable.
- Preventing HCMV infection is critical due to its potential for lifelong health consequences in infants and severe disease in vulnerable populations.
Purpose of the Study:
- To review current knowledge on natural immunity against HCMV, encompassing innate and adaptive responses.
- To analyze the outcomes of past HCMV vaccine clinical trials, identifying successes and failures.
- To propose innovative vaccine strategies for next-generation HCMV vaccine development.
Main Methods:
- Literature review of natural immunity against HCMV.
- Analysis of human clinical trial data for HCMV vaccines.
- Evaluation of animal models for HCMV research.
- Synthesis of findings to inform future vaccine design.
Main Results:
- Natural HCMV infection elicits complex immune responses, but protective correlates are not fully understood.
- Previous vaccine trials have faced challenges, highlighting the need for improved approaches.
- Animal models provide valuable insights but do not fully replicate human HCMV infection.
Conclusions:
- Harnessing knowledge of protective immunity is key to developing effective HCMV vaccines.
- Novel technologies and vaccine concepts are essential for advancing HCMV vaccine development.
- Future strategies should integrate immunological insights with innovative technological approaches.
Abstract:
Human cytomegalovirus (HCMV) infection, the most common cause of congenital disease globally, affecting an estimated 1 million newborns annually, can result in lifelong sequelae in infants, such as sensorineural hearing loss and brain damage. HCMV infection also leads to a significant disease burden in immunocompromised individuals. Hence, an effective HCMV vaccine is urgently needed to prevent infection and HCMV-associated diseases. Unfortunately, despite more than five decades of vaccine development, no successful HCMV vaccine is available. This review summarizes what we have learned from acquired natural immunity, including innate and adaptive immunity; the successes and failures of HCMV vaccine human clinical trials; the progress in related animal models; and the analysis of protective immune responses during natural infection and vaccination settings. Finally, we propose novel vaccine strategies that will harness the knowledge of protective immunity and employ new technology and vaccine concepts to inform next-generation HCMV vaccine development.
More Related Videos
05:53Use of In vivo Imaging to Monitor the Progression of Experimental Mouse Cytomegalovirus Infection in Neonates
Published on: July 6, 2013
08:52Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
Published on: May 27, 2011
Related Concept Videos
01:29Microorganisms in Medicine and Therapeutics
01:22Development of Immunocompetence
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
01:29Immune Response Against Viral Pathogens
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
01:23Immunological Memory
What is Immunological Memory?
Immunological memory is an integral function of the immune system that allows it to recognize and react more rapidly and effectively to pathogens previously encountered. This feature...
01:51Vaccinations